OBJECTIVE: Recent studies reported a lower human papillomavirus 16 (HPV16) prevalence in cervical precancer among African American than Caucasian women in the general population. We assessed this relationship in women with HIV. DESIGN: Women living with or at risk for HIV in the Women's Interagency HIV Study were followed semi-annually with Pap tests, colposcopy/histology (if indicated), and collection of cervicovaginal lavage samples for HPV testing by PCR. Racial and ethnic groups were defined using genomic Ancestry Informative Markers (AIMs). RESULTS: Among 175 cases of cervical intraepithelial neoplasia 3 or worse (CIN-3+), 154 were diagnosed in women with HIV. African American (27%) and Hispanic (37%) cases were significantly less likely than Caucasian (62%) women to test positive for HPV16 (P = 0.01). In multivariate logistic regression models, these associations remained significant for African Americans (odds ratio = 0.13; 95% confidence interval (CI) 0.04-0.44; P = 0.001) but not Hispanics, after controlling for HIV status, CD4 count, history of AIDS, age, smoking, and sexual behavior. Limiting the analysis to women with HIV did not change the findings. CONCLUSION: HPV16 prevalence is lower in African American compared with Caucasian women with HIV and cervical precancer, independent of immune status. Future studies to determine why these racial differences exist are warranted, and whether there are similar associations between race and invasive cervical cancer in women with HIV. Further, HPV types not covered by quadrivalent and bivalent vaccines may play an especially important role in cervical precancer among HIV-positive African American women, a possible advantage to using nonavalent HPV vaccine in this population.
OBJECTIVE: Recent studies reported a lower human papillomavirus 16 (HPV16) prevalence in cervical precancer among African American than Caucasian women in the general population. We assessed this relationship in women with HIV. DESIGN: Women living with or at risk for HIV in the Women's Interagency HIV Study were followed semi-annually with Pap tests, colposcopy/histology (if indicated), and collection of cervicovaginal lavage samples for HPV testing by PCR. Racial and ethnic groups were defined using genomic Ancestry Informative Markers (AIMs). RESULTS: Among 175 cases of cervical intraepithelial neoplasia 3 or worse (CIN-3+), 154 were diagnosed in women with HIV. African American (27%) and Hispanic (37%) cases were significantly less likely than Caucasian (62%) women to test positive for HPV16 (P = 0.01). In multivariate logistic regression models, these associations remained significant for African Americans (odds ratio = 0.13; 95% confidence interval (CI) 0.04-0.44; P = 0.001) but not Hispanics, after controlling for HIV status, CD4 count, history of AIDS, age, smoking, and sexual behavior. Limiting the analysis to women with HIV did not change the findings. CONCLUSION: HPV16 prevalence is lower in African American compared with Caucasian women with HIV and cervical precancer, independent of immune status. Future studies to determine why these racial differences exist are warranted, and whether there are similar associations between race and invasive cervical cancer in women with HIV. Further, HPV types not covered by quadrivalent and bivalent vaccines may play an especially important role in cervical precancer among HIV-positive African American women, a possible advantage to using nonavalent HPV vaccine in this population.
Authors: Xiaonan Xue; Stephen J Gange; Ye Zhong; Robert D Burk; Howard Minkoff; L Stewart Massad; D Heather Watts; Mark H Kuniholm; Kathryn Anastos; Alexandra M Levine; Melissa Fazzari; Gypsyamber D'Souza; Michael Plankey; Joel M Palefsky; Howard D Strickler Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-01 Impact factor: 4.254
Authors: Jane R Montealegre; Indu Varier; Christina G Bracamontes; Laura M Dillon; Martial Guillaud; Andrew G Sikora; Michele Follen; Karen Adler-Storthz; Michael E Scheurer Journal: Ethn Health Date: 2017-09-04 Impact factor: 2.772
Authors: Jennifer S Smith; Lisa Lindsay; Brooke Hoots; Jessica Keys; Silvia Franceschi; Rachel Winer; Gary M Clifford Journal: Int J Cancer Date: 2007-08-01 Impact factor: 7.396
Authors: Diane Solomon; Diane Davey; Robert Kurman; Ann Moriarty; Dennis O'Connor; Marianne Prey; Stephen Raab; Mark Sherman; David Wilbur; Thomas Wright; Nancy Young Journal: JAMA Date: 2002-04-24 Impact factor: 56.272
Authors: L Stewart Massad; Xianhong Xie; Gypsyamber D'Souza; Teresa M Darragh; Howard Minkoff; Rodney Wright; Christine Colie; Lorraine Sanchez-Keeland; Howard D Strickler Journal: Am J Obstet Gynecol Date: 2014-12-10 Impact factor: 8.661
Authors: Dana Whittemore; Lili Ding; Lea E Widdice; Darron A Brown; David I Bernstein; Eduardo L Franco; Jessica A Kahn Journal: J Womens Health (Larchmt) Date: 2016-10-18 Impact factor: 2.681
Authors: Alison G Abraham; Gypsyamber D'Souza; Yuezhou Jing; Stephen J Gange; Timothy R Sterling; Michael J Silverberg; Michael S Saag; Sean B Rourke; Anita Rachlis; Sonia Napravnik; Richard D Moore; Marina B Klein; Mari M Kitahata; Gregory D Kirk; Robert S Hogg; Nancy A Hessol; James J Goedert; M John Gill; Kelly A Gebo; Joseph J Eron; Eric A Engels; Robert Dubrow; Heidi M Crane; John T Brooks; Ronald J Bosch; Howard D Strickler Journal: J Acquir Immune Defic Syndr Date: 2013-04-01 Impact factor: 3.731
Authors: Howard D Strickler; Joel M Palefsky; Keerti V Shah; Kathryn Anastos; Robert S Klein; Howard Minkoff; Ann Duerr; L Stewart Massad; David D Celentano; Charles Hall; Melissa Fazzari; Susan Cu-Uvin; Melanie Bacon; Paula Schuman; Alexandra M Levine; Amanda J Durante; Stephen Gange; Sandra Melnick; Robert D Burk Journal: J Natl Cancer Inst Date: 2003-07-16 Impact factor: 13.506
Authors: Marla J Keller; Robert D Burk; L Stewart Massad; Isam-Eldin Eltoum; Nancy A Hessol; Philip E Castle; Kathryn Anastos; Xianhong Xie; Howard Minkoff; Xiaonan Xue; Gypsyamber D'Souza; Lisa Flowers; Alexandra M Levine; Christine Colie; Lisa Rahangdale; Margaret A Fischl; Joel M Palefsky; Howard D Strickler Journal: Clin Infect Dis Date: 2015-07-17 Impact factor: 9.079
Authors: Adriana C Vidal; Jennifer S Smith; Fidel Valea; Rex Bentley; Maggie Gradison; Kimberly S H Yarnall; Anne Ford; Francine Overcash; Kathy Grant; Susan K Murphy; Cathrine Hoyo Journal: Cancer Causes Control Date: 2014-06-14 Impact factor: 2.506
Authors: Philip E Castle; Robert D Burk; Leslie S Massad; Isam-Eldin Eltoum; Charles B Hall; Nancy A Hessol; Kathryn Anastos; Xianhong Xie; Howard Minkoff; Xiaonan Xue; Gypsyamber D'Souza; Lisa Flowers; Christine Colie; Lisa Rahangdale; Margaret A Fischl; Joel M Palefsky; Howard D Strickler Journal: Int J Cancer Date: 2019-10-18 Impact factor: 7.396
Authors: Megan A Clarke; Carolann Risley; Mary W Stewart; Kim R Geisinger; Laree M Hiser; Jody C Morgan; Kenyata J Owens; Krishna Ayyalasomayajula; Rhonda M Rives; Ashish Jannela; Dianne E Grunes; Lei Zhang; Mark Schiffman; Sarah Wagner; Joseph Boland; Sara Bass; Nicolas Wentzensen Journal: Cancer Med Date: 2021-11-03 Impact factor: 4.452
Authors: Howard D Strickler; Marla J Keller; Nancy A Hessol; Isam-Eldin Eltoum; Mark H Einstein; Philip E Castle; L Stewart Massad; Lisa Flowers; Lisa Rahangdale; Jessica M Atrio; Catalina Ramirez; Howard Minkoff; Adaora A Adimora; Igho Ofotokun; Christine Colie; Megan J Huchko; Margaret Fischl; Rodney Wright; Gypsyamber D'Souza; Jason Leider; Olga Diaz; Lorraine Sanchez-Keeland; Sadeep Shrestha; Xianhong Xie; Xiaonan Xue; Kathryn Anastos; Joel M Palefsky; Robert D Burk Journal: Clin Infect Dis Date: 2021-05-04 Impact factor: 9.079